Patent ID: 6492386
Filing Date: 2002-12-10
Classification: A61P,C07D

Abstract:
A method for treating a disease or condition in a mammal in need thereof, wherein the &agr;7 nicotinic acetylcholine receptor is implicated, wherein the disease or condition is any one of or combination of attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain comprising administering to the mammal a therapeutically effective amount of a compound of the Formula I: or pharmaceutically acceptable salts thereof, wherein X is O or S;R1 is independently selected from the group consisting of â€”H, alkyl, cycloalkyl, halogenated alkyl, and aryl; Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms; Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+1) substituent(s) independently selected from â€”F, â€”Cl, â€”Br, or â€”I where n is the maximum number of carbon atoms in the moiety; Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms; Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl; Substituted phenyl is a phenyl either having 1-4 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I, or having 1 substituent selected from â€”R12 and 0-3 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I; Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I, or having 1 substituent selected from â€”R12 and 0-3 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety; R2 is â€”H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl; Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I and further having 1 substituent selected from â€”OR10, â€”SR10, â€”NR10R10, â€”C(O)R10, â€”C(O)NR10R10, â€”CN, â€”NR10C(O)R10, â€”S(O)2NR10R10, â€”NR10S(O)2R10, â€”NO2, â€”R7, â€”R9, phenyl, or substituted phenyl; Substituted benzyl is a benzyl either having 1-4 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I, or having 1 substituent selected from â€”R12 and 0-3 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I, provided that all substitution is on the phenyl ring of the benzyl; R3 is selected from the group consisting of â€”H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, â€”R7, â€”R9, â€”OR8, â€”SR8, â€”F, â€”Cl, â€”Br, â€”I, â€”NR8R8, â€”C(O)R8, â€”CN, â€”C(O)NR8R8, â€”NR8C(O)R8, â€”S(O)R8, â€”OS(O)2R8, â€”NR8S(O)2R8, â€”NO2, and â€”N(H)C(O)N(H)R8; Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond; Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2nâˆ’1) substituent(s) independently selected from â€”F, â€”Cl, â€”Br, or â€”I where n is the maximum number of carbon atoms in the moiety; Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from â€”F, or â€”Cl, and further having 1 substituent selected from â€”R7, â€”R9, â€”OR10, â€”SR10, â€”NR10R10, â€”C(O)R10, â€”C(O)NR10R10, â€”NR10C(O)R10, â€”S(O)2NR10R10, â€”NR10S(O)2R10, â€”CN, phenyl, or substituted phenyl; Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond; Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2nâˆ’3) substituent(s) independently selected from â€”F, â€”Cl, â€”Br, or â€”I where n is the maximum number of carbon atoms in the moiety; Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from â€”F, or â€”Cl, and further having 1 substituent selected from â€”R7, â€”R9, â€”OR10, â€”SR10, â€”NR10R10, â€”C(O)R10, â€”C(O)NR10R10, â€”NR10C(O)R10, â€”S(O)2NR10R10, â€”NR10S(O)2R10, â€”CN, phenyl, or substituted phenyl; Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from â€”F, or â€”Cl; Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from â€”F, or â€”Cl, and further having 1 substituent selected from â€”OR10, â€”SR10, â€”NR10R10, â€”C(O)R10, â€”CN, â€”C(O)NR10R10, â€”NR10C(O)R10, â€”S(O)2NR10R10, â€”NR10S(O)2R10, â€”NO2, phenyl, or substituted phenyl; Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being â€”Sâ€”, â€”N(R3)â€”, or â€”Oâ€”; Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being â€”Sâ€”, â€”N(R3)â€”, or â€”Oâ€”, and having 1-4 substituents independently selected from â€”F, or â€”Cl; Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being â€”Sâ€”, â€”N(R3)â€”, or â€”Oâ€” and having 0-3 substituents independently selected from â€”F, or â€”Cl, and further having 1 substituent selected from â€”OR10, â€”SR10, â€”NR10R10, â€”C(O)R10, â€”C(O)NR10R10, â€”CN, â€”NR10C(O)R10, â€”NO2, â€”S(O)2NR10R10, â€”NR10S(O)2R10, phenyl, or substituted phenyl; R4 is selected from the group consisting of â€”Oâ€”R5, â€”Sâ€”R5, â€”S(O)â€”R5, â€”C(O)â€”R5, and alkyl substituted on the &ohgr; carbon with R5 where said &ohgr; carbon is determined by counting the longest carbon chain of the alkyl moiety with the C-1 carbon being the carbon attached to the phenyl ring of the core molecule and the &ohgr; carbon being the carbon furthest from said C-1 carbon; R5 is selected from aryl, R7, or R9; R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of â€”Oâ€”, &boxH;Nâ€”, â€”N(R14)â€”, and â€”Sâ€”, and having 0-1 substituent selected from â€”R12 and 0-3 substituents independently selected from â€”F, â€”Cl, â€”Br, or â€”I, or R7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula wherein E is O, S, or NR14, wherein E and G are independently selected from CR18, O, S, or NR14, and A is CR18 or N, or wherein E and G are independently selected from CR18, O, S, or NR14, and A is CR18 or N, each 9-membered fused-ring moiety having 0-1 substituent selected from â€”R12 and 0-3 substituent(s) independently selected from â€”F, â€”Cl, â€”Br, or â€”I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;Each R8 is independently selected from â€”H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, R9, phenyl, or substituted phenyl; R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from &boxH;Nâ€” and having 0-1 substituent selected from â€”R12 and 0-3 substituent(s) independently selected from â€”F, â€”Cl, â€”Br, or â€”I, or 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from &boxH;Nâ€”, including quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from â€”R12 and 0-3 substituent(s) independently selected from â€”F, â€”Cl, â€”Br, or â€”I and having a bond directly or indirectly attached to the core molecule where valency allows; Each R10 is independently selected from â€”H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R13, cycloalkyl substituted with 1 substituent selected from R13, heterocycloalkyl substituted with 1 substituent selected from R13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl; Each R11 is independently selected from â€”H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl; R12 is selected from â€”OR11, â€”SR11, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, â€”NR11R11, â€”C(O)R11, â€”NO2, â€”C(O)NR11R11, â€”CN, â€”NR11C(O)R11, â€”S(O)2NR11R11, or â€”NR11S(O)2R11; R13 is selected from â€”OR11, â€”SR11, â€”NR11R11, â€”C(O)R11, â€”C(O)NR11R11, â€”CN, â€”CF3, â€”NR11C(O)R11, â€”S(O)2NR11R11, â€”NR11S(O)2R11, or â€”NO2; R14 is selected from â€”H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or substituted phenyl; Each R15 is independently selected from alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, R9, phenyl, or substituted phenyl; Each R16 is independently selected from cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, R9, phenyl, or substituted phenyl; R17 is selected from cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl; and Each R18 is independently selected from â€”H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, â€”OR11, â€”SR11, â€”NR11R11, â€”C(O)R11, â€”NO2, â€”C(O)NR11R11, â€”CN, â€”NR11C(O)R11, â€”S(O)2NR11R11, or â€”NR11S(O)2R11, â€”F, â€”Cl, â€”Br, or â€”I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, â€”OR11, â€”SR11, â€”NR11R11, â€”C(O)R11, â€”NO2, â€”C(O)NR11R11, â€”CN, â€”NR11C(O)R11, â€”S(O)2NR11R11, or â€”NR11S(O)2R11, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from â€”F, â€”Cl, â€”Br, or â€”I.